News
London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...
This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback